• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对接受含顺铂、阿霉素、异环磷酰胺和依托泊苷化疗的骨肉瘤患者的临床过程进行评估,并在长达11年的长期随访中确定治疗后遗症。

Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin, adriamycin, ifosfamide, and etoposide and determination of the treatment sequels in a long-term 11-year follow-up.

作者信息

Aznab Mozaffar, Hematti Maryam

机构信息

Department of Internal Medicine, Talaghani Hospital, Kermanshah University of Medical Sciences, Kermanshah 6714415333, Iran.

Department of Obstetrics, Shahid Beheshti BLND, Kermanshah 6714415333, Iran.

出版信息

J Cancer Res Ther. 2017 Apr-Jun;13(2):291-296. doi: 10.4103/0973-1482.199447.

DOI:10.4103/0973-1482.199447
PMID:28643750
Abstract

AIM

The aim of this study was to evaluate the effect of adding etoposide and ifosfamide chemotherapy drugs to treatment regimen of patients affected with osteosarcoma and to determine the clinical process and response to treatment during a follow-up period of 11 years.

MATERIALS AND METHODS

Forty patients with osteosarcoma participated in this study from July 2005 to 2016. Treatments were started based on the following schema and after initial examinations including biochemical profile, checking for lung metastasis by simple radiography, chest computed tomography scan, and bones scan. The initial chemotherapy which consisted of four cycles of cisplatin and adriamycin alternative with ifosfamide and etoposide was provided. Afterward, resection of the primary tumor and also the metastatic lesions was performed in patients with lung metastasis in case they had radiological evidence of response to the treatment.

RESULTS

The mean of follow-up duration in this study was 50 months. Thirty-four patients did not have metastasis and six were metastatic. Of 34 patients, 18 had relapse and 16 patients never had relapse. Five patients experienced only local relapse, nine had only systemic relapse, and two patients had simultaneous systemic and local relapses. Thirteen patients had died. The mean of overall survival in patients was 81 months. The mean of survival in patients with and without primary metastasis was 30 and 90 months, respectively.

CONCLUSION

Favorable response to the treatment was obtained with an appropriate multiple disciplinary works in the osteosarcomas of extremities, and there were no considerable side effects and sequels in the long-term follow-up of these treatments.

摘要

目的

本研究旨在评估在骨肉瘤患者的治疗方案中添加依托泊苷和异环磷酰胺化疗药物的效果,并确定在11年随访期内的临床过程及对治疗的反应。

材料与方法

2005年7月至2016年,40例骨肉瘤患者参与了本研究。治疗基于以下方案开始,且在包括生化指标、通过简单X线摄影、胸部计算机断层扫描和骨扫描检查肺转移等初始检查之后进行。提供了由四个周期的顺铂和阿霉素交替联合异环磷酰胺和依托泊苷组成的初始化疗。之后,对于有肺转移且有影像学治疗反应证据的患者,进行原发性肿瘤及转移病灶的切除。

结果

本研究的平均随访时间为50个月。34例患者无转移,6例有转移。在34例无转移的患者中,18例复发,16例从未复发。5例仅发生局部复发,9例仅发生全身复发,2例同时发生全身和局部复发。13例患者死亡。患者的总生存期平均为81个月。有原发转移和无原发转移患者的生存期平均分别为30个月和90个月。

结论

通过对四肢骨肉瘤进行适当的多学科治疗,获得了良好的治疗反应,且这些治疗的长期随访中没有明显的副作用和后遗症。

相似文献

1
Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin, adriamycin, ifosfamide, and etoposide and determination of the treatment sequels in a long-term 11-year follow-up.对接受含顺铂、阿霉素、异环磷酰胺和依托泊苷化疗的骨肉瘤患者的临床过程进行评估,并在长达11年的长期随访中确定治疗后遗症。
J Cancer Res Ther. 2017 Apr-Jun;13(2):291-296. doi: 10.4103/0973-1482.199447.
2
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.肢体骨肉瘤伴同步肺转移的新辅助化疗:顺铂、阿霉素、大剂量甲氨蝶呤和异环磷酰胺治疗。
Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339.
3
Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.动脉内注射顺铂与静脉注射阿霉素治疗肢体非转移性骨肉瘤:台湾某单一机构的经验
Chang Gung Med J. 2009 Jan-Feb;32(1):72-80.
4
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).非转移性肢体骨肉瘤的高效低毒剂量密集型试验方案(SCOS 89)
Cancer Chemother Pharmacol. 2015 Nov;76(5):909-16. doi: 10.1007/s00280-015-2865-x. Epub 2015 Sep 13.
5
A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.顺铂、异环磷酰胺和表柔比星联合化疗用于非转移性和肢体骨肉瘤成人患者的II期研究。
Oncology. 2007;72(3-4):255-60. doi: 10.1159/000113017. Epub 2008 Jan 10.
6
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.SFOP OS94:一项随机试验,比较术前高剂量甲氨蝶呤加阿霉素与高剂量甲氨蝶呤加依托泊苷和异环磷酰胺用于骨肉瘤患者的疗效。
Eur J Cancer. 2007 Mar;43(4):752-61. doi: 10.1016/j.ejca.2006.10.023. Epub 2007 Jan 30.
7
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.伴有同步肺转移的四肢骨肉瘤:44例接受新辅助化疗患者的长期结果
J Chemother. 1998 Feb;10(1):69-76. doi: 10.1179/joc.1998.10.1.69.
8
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.肢体骨肉瘤的新辅助化疗:原发肿瘤对甲氨蝶呤、顺铂、阿霉素和异环磷酰胺术前治疗的良好反应。初步结果。
Chir Organi Mov. 1995 Jan-Mar;80(1):1-10.
9
Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.高剂量异环磷酰胺、阿霉素、顺铂及高剂量甲氨蝶呤用于肢体非转移性骨肉瘤的新辅助和辅助化疗:日本一项II期试验
J Chemother. 2013 Feb;25(1):41-8. doi: 10.1179/1973947812Y.0000000055.
10
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.依托泊苷与大剂量异环磷酰胺用于新诊断转移性骨肉瘤的II/III期试验:一项儿科肿瘤学组试验
J Clin Oncol. 2002 Jan 15;20(2):426-33. doi: 10.1200/JCO.2002.20.2.426.

引用本文的文献

1
LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review.长链非编码RNA作为骨肉瘤潜在的预后/诊断标志物及导致耐药的因素:综述
Front Endocrinol (Lausanne). 2024 Jul 2;15:1415722. doi: 10.3389/fendo.2024.1415722. eCollection 2024.
2
The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand.骨肉瘤全身化疗后的生存结果、预后因素及不良事件:一项基于泰国北部癌症转诊中心经验的回顾性观察研究。
Cancers (Basel). 2023 Mar 26;15(7):1979. doi: 10.3390/cancers15071979.
3
Origin and Therapies of Osteosarcoma.
骨肉瘤的起源与治疗
Cancers (Basel). 2022 Jul 19;14(14):3503. doi: 10.3390/cancers14143503.
4
Osteosarcoma: a review of current and future therapeutic approaches.骨肉瘤:当前和未来治疗方法的综述。
Biomed Eng Online. 2021 Mar 2;20(1):24. doi: 10.1186/s12938-021-00860-0.
5
Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.研究骨肉瘤患者免疫组化染色中血管内皮生长因子与HER-2neu的关系及其与转移和死亡率的相关性。
Asian Pac J Cancer Prev. 2020 Oct 1;21(10):3005-3009. doi: 10.31557/APJCP.2020.21.10.3005.
6
Nucleus size and DNA accessibility are linked to the regulation of paraspeckle formation in cellular differentiation.核大小和 DNA 可及性与细胞分化中核仁小体形成的调控有关。
BMC Biol. 2020 Apr 22;18(1):42. doi: 10.1186/s12915-020-00770-y.
7
Development and validation of a nomogram for osteosarcoma-specific survival: A population-based study.骨肉瘤特异性生存列线图的开发与验证:一项基于人群的研究。
Medicine (Baltimore). 2019 Jun;98(23):e15988. doi: 10.1097/MD.0000000000015988.
8
Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.Livin和胎盘生长因子(PlGF)在人骨肉瘤中的表达与肿瘤进展及临床预后相关。
Oncol Lett. 2018 Oct;16(4):4953-4960. doi: 10.3892/ol.2018.9239. Epub 2018 Jul 31.